TY - JOUR
T1 - Efficacy of bupropion and the selective serotonin reuptake inhibitors in the treatment of anxiety symptoms in major depressive disorder
T2 - A meta-analysis of individual patient data from 10 double-blind, randomized clinical trials
AU - Papakostas, George I.
AU - Trivedi, Madhukar H.
AU - Alpert, Jonathan E.
AU - Seifert, Cheryl A.
AU - Krishen, Alok
AU - Goodale, Elizabeth P.
AU - Tucker, Vivian L.
N1 - Funding Information:
We thank Sajida Chughtai B.S. and Russel Hinkle B.S. from GlaxoSmithKline for their help with the statistical programming. Supported by NIMH Grant K23 MH069629 (salary of GIP and CAS) and by GlaxoSmithKline (salary for statistical programming and support, and salary of co-authors AK, EPG, VLT).
PY - 2008/1
Y1 - 2008/1
N2 - The goal of this work was to compare the efficacy of the norepinephrine-dopamine reuptake inhibitor bupropion with the selective serotonin reuptake inhibitors (SSRIs) in the treatment of anxiety symptoms in major depressive disorder (MDD). Ten double-blind, randomized studies, involving a total of 2890 bupropion-, SSRI- or placebo- treated patients were pooled. Anxiety symptoms of depression were defined using the Hamilton depression rating scale (HDRS) Anxiety-Somatization factor (HDRS-AS) score, as well as the Hamilton anxiety scale (HAM-A) score. Both bupropion and the SSRIs led to a comparable degree of improvement in anxiety symptoms, defined using the HDRS-AS score (-3.8 ± 2.8 vs. -3.9 ± 2.8, p = 0.130) or HAM-A score (-8.8 ± 7.2 vs. -9.1 ± 7.0, p = 0.177). There was no consistent difference in the time to anxiolysis between the two treatment groups. In addition, there was no difference in the proportion of bupropion- and SSRI- remitters who continued to experience residual anxiety, defined as a HDRS-AS score >0 at endpoint (69.2% vs. 74.7%, p = 0.081) or a HAM-A score >7 at endpoint (9.5% vs. 8.4%, p = 0.284). Finally, there was no statistically significant difference in the severity of residual anxiety symptoms between bupropion- or SSRI- treated patients with remitted depression, defined using the HDRS-AS (1.15 ± 1.14 vs. 1.25 ± 1.09, p = 0.569), or HAM-A scores at endpoint (3.30 ± 2.89 vs. 3.31 ± 2.89, p = 0.552). Contrary to clinician impression, there does not appear to be any difference in the anxiolytic efficacy of bupropion and the SSRIs when used to treat MDD.
AB - The goal of this work was to compare the efficacy of the norepinephrine-dopamine reuptake inhibitor bupropion with the selective serotonin reuptake inhibitors (SSRIs) in the treatment of anxiety symptoms in major depressive disorder (MDD). Ten double-blind, randomized studies, involving a total of 2890 bupropion-, SSRI- or placebo- treated patients were pooled. Anxiety symptoms of depression were defined using the Hamilton depression rating scale (HDRS) Anxiety-Somatization factor (HDRS-AS) score, as well as the Hamilton anxiety scale (HAM-A) score. Both bupropion and the SSRIs led to a comparable degree of improvement in anxiety symptoms, defined using the HDRS-AS score (-3.8 ± 2.8 vs. -3.9 ± 2.8, p = 0.130) or HAM-A score (-8.8 ± 7.2 vs. -9.1 ± 7.0, p = 0.177). There was no consistent difference in the time to anxiolysis between the two treatment groups. In addition, there was no difference in the proportion of bupropion- and SSRI- remitters who continued to experience residual anxiety, defined as a HDRS-AS score >0 at endpoint (69.2% vs. 74.7%, p = 0.081) or a HAM-A score >7 at endpoint (9.5% vs. 8.4%, p = 0.284). Finally, there was no statistically significant difference in the severity of residual anxiety symptoms between bupropion- or SSRI- treated patients with remitted depression, defined using the HDRS-AS (1.15 ± 1.14 vs. 1.25 ± 1.09, p = 0.569), or HAM-A scores at endpoint (3.30 ± 2.89 vs. 3.31 ± 2.89, p = 0.552). Contrary to clinician impression, there does not appear to be any difference in the anxiolytic efficacy of bupropion and the SSRIs when used to treat MDD.
KW - Anxiety
KW - Bupropion
KW - Depression
KW - MDD
KW - SSRIs
KW - Treatment
UR - http://www.scopus.com/inward/record.url?scp=35848954053&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=35848954053&partnerID=8YFLogxK
U2 - 10.1016/j.jpsychires.2007.05.012
DO - 10.1016/j.jpsychires.2007.05.012
M3 - Article
C2 - 17631898
AN - SCOPUS:35848954053
SN - 0022-3956
VL - 42
SP - 134
EP - 140
JO - Journal of Psychiatric Research
JF - Journal of Psychiatric Research
IS - 2
ER -